Johnson & Johnson agreed to acquire Halda Therapeutics for $3.05 billion in cash to gain the company's regulated induced proximity targeting chimera (RIPTAC) technology and lead candidate HLD-0915 for metastatic castration-resistant prostate cancer. J&J said the buyout brings a novel 'hold-and-kill' bifunctional modality designed to circumvent common resistance mechanisms in oncology. Halda presented early phase data showing PSA reductions and objective responses in heavily pretreated patients; J&J characterized the initial results as 'impressive' and plans to accelerate ongoing studies. The acquisition reflects continued Big Pharma appetite for platform technologies that address drug resistance and add differentiated oral oncology assets.